Oncology
Latest news
915 articles · 20 / page
Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma
Recent clinical trials reveal that LBL-007, a novel anti-LAG-3 antibody, significantly enhances treatment outcomes for advanced nasopharyngeal carcinoma when combined with PD-1 inhibitors, marking a potential shift in the standard of care f
AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma
This Phase 1/1b study demonstrates that IK-175, an oral AHR inhibitor, is safe and clinically active in PD-1-refractory urothelial carcinoma, showing target engagement and preliminary efficacy both as monotherapy and in combination with niv
FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?
A multi-center phase II trial demonstrates that mid-treatment FDG-PET imaging can safely identify patients with HPV+ oropharyngeal cancer for radiation dose reduction, resulting in non-inferior tumor control and significantly improved quali
Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?
The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower
Denosumab Shows Insufficient Activity in Recurrent Osteosarcoma: Results from a Children’s Oncology Group Phase 2 Trial
A Phase 2 trial by the Children’s Oncology Group found that denosumab, despite its success in other bone-related conditions, failed to meet efficacy benchmarks for recurrent or refractory osteosarcoma, showing no objective responses in pati
Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer
This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally
KEYLYNK-009: Is Olaparib Plus Pembrolizumab a Viable Maintenance Strategy in Metastatic Triple-Negative Breast Cancer?
The KEYLYNK-009 trial investigated pembrolizumab plus olaparib as maintenance therapy for metastatic TNBC. While it did not meet primary PFS or OS endpoints compared to chemotherapy, the combination showed a favorable trend in BRCA-mutated
Precision Management of KRAS G12V-Mutated NSCLC: Molecular Insights and Therapeutic Strategies
This article synthesizes recent findings on the KRAS G12V mutation in non-small cell lung cancer, highlighting its unique molecular profile, strong association with smoking, and superior response to immunotherapy compared to traditional che
INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC
The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma
Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance
A multi-omics analysis from the AURORA program reveals that metastatic breast cancer carries a significantly higher burden of gene fusions than primary tumors. Acquired fusions, particularly involving ESR1, are linked to genomic instability
Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis
A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcin
MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing crit
Eribulin Demonstrates Clinical Efficacy in Taxane-Pretreated Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
A Phase 2 study reveals that eribulin, a non-taxane microtubule inhibitor, provides meaningful objective responses and disease stability in patients with rare vascular sarcomas, including those previously treated with taxanes.
Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer
A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.
PET/CT-Guided Discontinuation of Immunotherapy in Metastatic Lung Cancer: A Paradigm Shift Toward Precision De-escalation
A landmark study from the nNGM reveals that PET/CT-guided discontinuation of immunotherapy in long-term lung cancer responders significantly improves survival and identifies second primary cancers, challenging the current practice of indefi
The Evolving Paradigm in High-Risk NMIBC: Critical Synthesis of Checkpoint Inhibitors and BCG Combination Therapy
A comprehensive meta-analysis of the POTOMAC, CREST, and ALBAN trials reveals that adding PD-(L)1 inhibitors to BCG improves event-free survival in high-risk NMIBC. However, increased toxicity and agent-specific variations in efficacy sugge
Molecular Imaging and PET-Guided Dose Escalation Revolutionize Salvage Radiotherapy: Insights from EMPIRE-1 and EMPIRE-2
The EMPIRE trials demonstrate that integrating molecular imaging and PET-guided dose escalation significantly improves event-free survival in patients requiring salvage radiotherapy for prostate cancer recurrence.
Multimodal AI Outperforms Clinical Nomograms in Predicting Metastasis for Post-Prostatectomy Biochemical Recurrence
A validated multimodal AI model using digital pathology and clinical data significantly improves risk stratification for prostate cancer patients with biochemical recurrence, identifying those who derive the greatest benefit from salvage ho
Audit and Feedback in NMIBC Surgery: Improved Documentation Does Not Translate to Better Clinical Outcomes
A global cluster randomized trial (RESECT) demonstrates that while audit and feedback improve surgical documentation in non-muscle-invasive bladder cancer, they fail to enhance detrusor muscle sampling, adjuvant chemotherapy use, or early r
The NanoKnife Revolution: A Non-Thermal Leap Forward in Precision Prostate Cancer Care
The PRESERVE trial demonstrates that Irreversible Electroporation (IRE) using the NanoKnife System is a safe and effective focal therapy for intermediate-risk prostate cancer, offering high success rates while preserving urinary and sexual
Browse by specialty
Open language-specific specialty feeds and department pages.